Objectives: To elucidate loci in Neisseria gonorrhoeae implicated in reduced susceptibility to ceftriaxone. Conclusions: Reduced susceptibility to ceftriaxone in N. gonorrhoeae is mediated by porB1b alleles and is associated with specific mutations in PBP2 and in the DNA binding and dimerization domains of MtrR.
Introduction
Neisseria gonorrhoeae has developed resistance to antimicrobial agents including sulfonamides, penicillins, tetracycline and, more recently, to fluoroquinolones. 1 This resistance to different antimicrobial agents has now left third-generation cephalosporins, including the oral drugs ceftibuten, cefixime and the parenteral drug ceftriaxone, as first-line therapy for the treatment of N. gonorrhoeae infections.
1,2 However, gonococcal resistance or reduced susceptibility to third-generation cephalosporins has threatened the effective treatment of gonorrhoea. 2, 3 Clinical treatment failures of ceftibuten and cefixime have been reported, 4 -6 and gonococcal isolates with increased MICs to cefixime or ceftriaxone have been observed in some regions. 3 An understanding of the molecular mechanism(s) of cephalosporin resistance would permit the development of methods for more effective detection and monitoring of the emergence of this resistance. Mutations at various loci, singularly or in combination, are associated with chromosomally mediated resistance to different classes of antibiotics in N. gonorrhoeae. 2, 7 An insertion of Asp-346 or other mutations in the transpeptidase domain (AA340 -570) of gonococcal penicillin binding protein 2 (PBP2) are associated with altered protein affinity to penicillin and penicillin resistance in N. gonorrhoeae. 8 A mosaic PBP2, which was first identified as PBP2 mutation pattern X, 9 may cause increased MICs to cefixime (≥0.25 mg/L) in N. gonorrhoeae isolates. 9 -11 It has also been reported that A501V/G545S double mutations in PBP2 affect ceftriaxone or cefixime susceptibility. 11, 12 An L421P mutation in penicillin binding protein 1 (PBP1) decreased rates of acylation by b-lactam antibiotics and reduced protein affinity to penicillin, resulting in high-level penicillin resistance. 13 The L421P mutation has also been noted in clinical N. gonorrhoeae isolates with reduced susceptibility to b-lactam antibiotics, including third-generation cephalosporins. 13 -15 MtrR represses the expression of the N. gonorrhoeae MtrC/D/E efflux system. 16 -18 Mutations in MtrR, including A39T and G45D mutations in the DNA binding domain and H105Y or E202G mutations in the dimerization domain of MtrR, cause resistance to hydrophobic antimicrobial agents. 19 A single nucleotide deletion (2A) within the 13 bp inverted repeat of the mtrR promoter reduces MtrR expression, 17 thereby alleviating repression of the efflux pump. Mutations in the DNA binding domain of MtrR or within the mtrR promoter region have been associated with reduced susceptibility of N. gonorrhoeae to ceftriaxone or erythromycin. 7, 20 Gonococcal PorB allows the passage of small molecules, such as b-lactams and tetracyclines, through the outer membrane. 21, 22 Each gonococcal isolate contains either a porB1a or a porB1b allele, producing PIA or PIB proteins, respectively.
23,24
The PIA phenotype is associated with higher susceptibility to b-lactams and tetracyclines. 25, 26 Amino acid substitutions at Gly-120 and Ala-121 of loop 3 of PorB are associated with reduced susceptibility to b-lactams and tetracyclines, 25 -28 and recently G120K/A121D mutations were associated with reduced susceptibility to third-generation cephalosporins. 7, 29 We reported the presence and spread of gonococcal isolates with reduced susceptibility to ceftriaxone (CRO Red ; MIC¼ 0.125 -0.25 mg/L) in 2005 (11.9%, 19/159) 30 and in 2008 (19.7%, 14/71) in Shanghai, China. In the present study, we investigated molecular mechanisms contributing to a CRO Red phenotype by comparing mutation patterns for multiple loci (porB, mtrR, penA and ponA) in both CRO Red isolates and isolates from the same study that were susceptible to ceftriaxone (CRO S ; n¼ 32, MIC¼ 0.004-0.016 mg/L).
N. gonorrhoeae multi-antigen sequence typing (NG-MAST) and porB-based DNA sequence analyses 25, 31, 32 were performed to determine the clonality of CRO Red isolates. We determined that N. gonorrhoeae isolates with reduced susceptibility to ceftriaxone were non-clonal. We determined that a porB1b genotype is required but is insufficient for causing reduced susceptibility to ceftriaxone. We also determined that a wild-type (WT) MtrR protein or MtrR with double mutations (A39T/H105Y or G45D/H105Y) is associated with the CRO Red phenotype. Our results revealed that while the mosaic PBP2 pattern X was not present in these isolates, multiple mutations in the polymorphic transpeptidase domain of PBP2 may be associated with reduced susceptibility to ceftriaxone.
Materials and methods

Collection and identification of N. gonorrhoeae isolates
Clinical isolates of N. gonorrhoeae were consecutively collected from male patients at the Shanghai Skin Disease and STD Hospital (SSDSH) in 2005 (n ¼159) 30 and 2008 (n¼71). Gonococcal isolates were isolated, identified and grown as described previously. 30 Ethical approval for the study was obtained from the Ethics Committee of the Shanghai Municipal Bureau of Public Health (China) and the Ethics Board of the University of Saskatchewan (Canada). 
Antimicrobial susceptibility testing
The antimicrobial susceptibility of N. gonorrhoeae isolates to penicillin, tetracycline, ciprofloxacin, spectinomycin and ceftriaxone was determined at the SSDSH using the agar dilution method and interpretive MIC standards recommended by the CLSI 33 b-lactamase production (PPNG) was detected using nitrocefin. 33 Each MIC determination was performed in duplicate and included WHO reference strains A, B, C, D and E. 30 Chromosomal DNA extraction N. gonorrhoeae isolates were grown and stored at the SSDSH. Chromosomal DNA from each isolate was prepared using the Genomic DNA Purification Kit (Shanghai Promega Biological Products Ltd, Shanghai, China). 25, 30 DNA samples were shipped to the University of Saskatchewan (Canada) for DNA sequence analysis.
PCR amplification
To identify putative mutations that might be implicated in CRO Red , penA, mtrR, the mtrR promoter region, porB and ponA from each isolate were PCR amplified. To ascertain strain clonality, porB and tbpB were amplified for porB-based DNA sequence and NG-MAST analyses. 25, 31, 32 Primers used for PCR amplification of the targeted loci are described in Table 1 , including porB-F/porB-R, 25, 31, 32 tbpB-F/tbpB-R, 31,32 mtrR-F/ mtrR-R, 20 penA-F/penA-R 15,34 and ponA-F/ponA-R. 13, 35 For PCR amplifications, chromosomal DNA of N. gonorrhoeae FA1090 was used as a positive control and ddH 2 O was used as a negative control. The PCR mixture (50 mL) contained 2 mL of genomic DNA, 2.5 U of Taq DNA polymerase (New England Biolabs Ltd, Pickering, Ontario, Canada), 1× PCR buffer with 1.5 mM MgCl 2 , 0.25 mM dNTPs and 0.5 mM of each primer. Amplification (Thermo Cycler; Applied Biosystems, Streetsville, Ontario, Canada) was performed as follows: an initial denaturing step at 948C for 4 min, followed by 30 sequential cycles of 948C for 1 min, 558C for 1 min and 728C for 1 min, and a final extension phase at 728C for 10 min.
DNA sequencing and sequence analysis
Both strands of amplified DNA fragments were sequenced at the Plant Biotechnology Institute (National Research Council of Canada, Saskatoon, Saskatchewan) as previously described, 25 using the same primers as for PCR amplifications (Table 1) . DNA sequences were verified and edited as described previously. 25, 32 DNA sequences were translated into deduced amino acid sequences using Proteomics and Sequence Tools (http://ca. expasy.org/; 21 December 2009, date last accessed). Amino acid sequences were aligned with their respective prototypes in N. gonorrhoeae, for which GenBank accession numbers are shown in Table 1 .
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NG-MAST and porB-based DNA sequence analysis
Analysis of NG-MAST sequence types (STs) was performed as previously described. 25, 31, 32 porB-based phylogenetic analysis was performed using Clustal X and phylogenetic trees were viewed using TreeView. 25 
Statistical analysis
Yates' x 2 tests were used for statistical analysis. 36 Significance was set at a P value of ,0.05.
DNA sequence submission
DNA sequences were submitted to GenBank [National Center of Biotechnology Information (NCBI); http://www.ncbi.nlm.nih.gov/genbank/submit. html]. GenBank accession numbers included those for penA (HM490125-HM400141), porB1a (HM481249-HM491254), porB1b (HM490092-HM490124), mtrR (HM467704-HM467711), mtrR promoter regions (HM446632 and HM446633) and ponA (HM467700-HM467703). NG-MAST STs were stored at the NG-MAST web site (www.ng-mast.net). 31 
Results
Antimicrobial resistance phenotypes were similar between N. gonorrhoeae CRO Red and CRO S isolates
The ceftriaxone MICs of the CRO Red and CRO S N. gonorrhoeae isolates differed by at least 4-fold. The MIC 50 s and MIC 90 s to penicillin, tetracycline, ciprofloxacin or spectinomycin for the two groups were within a 2-fold dilution (data not shown). All isolates were susceptible to spectinomycin. There was no significant difference (P . N. gonorrhoeae porB1b is associated with reduced susceptibility to ceftriaxone
The overall percentage of isolates carrying a PIB phenotype (Table 2 ) was significantly higher in CRO Red (89.3%, 25/28) isolates than in CRO S (59.4%, 19/32) isolates (P ¼ 0.02). G120K/ A121D double mutations in PIB have been associated with reduced susceptibility of N. gonorrhoeae isolates to ceftriaxone. 37 We did not find this to be the case with the isolates studied from Shanghai (Table 2 ). In CRO Red PIB isolates (n¼ 25), the amino acid substitutions observed at residues G120 and/or A121 included G120K/A121D (68.0%), G120K/A121N/G (20.0%) and G120D alone (12.0%). In CRO S PIB isolates (n¼19), similar amino acid substitutions were observed, i.e. G120K/A121D (84.2%), G120K/A121N/G (5.3%) and G120D alone (5.3%). One CRO S PIB isolate had no mutations at residues G120 and A121. 
Mutation patterns in PBP2 (penA)
Mutations in the transpeptidase domain of PBP2 (AA340 -570) have been implicated in reduced susceptibility to thirdgeneration cephalosporins. All isolates in this study had an Asp-346 insertion in PBP2 and all other amino acids between AA340 and AA500 of PBP2 were identical in both groups of isolates (data not shown).
Amino acid polymorphisms of the PBP2 transpeptidase domain were observed at 12 residues, i.e. Ala-501, Phe-504, Ala-510, Ala-516, His-541, Gly-542, Pro-551, Pro-552, Lys-555, Ile-556, Ile-563 and Ile566. The A501V/T mutation was present more frequently in the CRO Red isolates (78.6%) as compared with isolates that were CRO S (46.9%; P ¼0.02). However, when stratified by PorB type (i.e. PIA or PIB), the percentages of A501V/T mutations were similar between the CRO Red and CRO S isolates (P .0.05, data not shown). All isolates of both groups contained F504L, A510V and A516G mutations. Although mutations at the other 8 residues were present, their percentages between the CRO Red and CRO S isolates were not significantly different (P .0.05).
Twenty-four polymorphism patterns (I -XXIV) of PBP2 between AA340 -570 have been described previously. 10, 15, 37 Pattern X has been described as mosaic PBP2, 10 but was not observed in either CRO Red or CRO S isolates in this study. The patterns encountered in our study ( Molecular determinants associated with reduced susceptibility to ceftriaxone in N. gonorrhoeae isolates (Table 4) , i.e. patterns II or XVI (7.1%), V (10.7%), XIII (17.9%), XVII or XVIII (25.0%), XXI (10.7%), XXVII (10.7%) and IX, XXV, XXVI, XXVIII and XXIV (3.6% each). CRO S isolates (n¼ 32) exhibited eight polymorphism patterns, i.e. patterns II or XVI (15.6%), V (21.9%), IX (12.5%), XXI (25.0%) and XXVII (15.6%) and 1 (3.1%) isolate each for patterns IV, XVII or XVIII and XXX. Patterns XIII (17.9%), XXV (3.6%), XXVI (3.6%), XXVIII (3.6%) and XXIX (3.6%) were only present in CRO Red isolates, while patterns IV (3.1%) and XXX (3.1%) were only present in CRO S isolates. Noticeably, patterns XIII (17.9%) and XVII or XVIII (25.0%) were more prevalent in the CRO Red isolates as compared with the CRO S isolates (Table 4 ; P,0.001), and these patterns contained combinations of mutations of A501V/P551S or A501V/G542S. Patterns V and XXI accounted for a larger portion of CRO S isolates (46.9%, 15/32) as compared with CRO Red isolates (21.4%, 6/28) (Table 4 ; P ¼ 0.04). Patterns V and XXI did not have combined mutations of A501V/P551S or A501V/G542S (i.e. pattern V did not have A501V, although it had G542S, and pattern XXI did not have P551S/L or G542S, although it had A501V).
Isolates (CRO Red or CRO S ) were stratified by PorB type to analyse whether mutations in PBP2 were associated with the PorB type. Forty-four percent of PIB CRO Red isolates (n¼ 25) exhibited mutation patterns XIII (16.0%, 4/25) or XVII or XVIII (28.0%, 7/25), while the PIB CRO S isolates (n¼ 19) were mostly pattern XXI (31.6%, 6/19). The 3 PIA CRO Red isolates exhibited patterns IX, XIII and XXV, while 13 PIA CRO S isolates were pattern II or XVI (23.1%, 3/13), V (30.8%, 4/13), IX (7.7%, 1/13), XXI (15.4%, 2/13) and XXVII (23.1%, 3/13).
L421P mutation in PBP1 (ponA) is not associated with reduced susceptibility to ceftriaxone
All the CRO Red isolates and 97.0% of the CRO S isolates carried an L421P mutation in PBP1 (P .0.05). One CRO S isolate had a double L421P/A375T mutation as well as a PIA phenotype.
Another CRO S isolate did not have mutations in PBP1 and exhibited a PIA phenotype. No other amino acid substitutions were observed in gonococcal PBP1 in this study except for L421P and A375T.
Clustering of CRO
Red isolates based on porB DNA sequence and NG-MAST analysis
The porB sequence types and NG-MAST STs of the N. gonorrhoeae isolates were diverse. The 3 porB1a CRO Red isolates exhibited 2 different porB sequences and 3 NG-MAST STs, while the 13 proB1a CRO S isolates exhibited 10 porB sequences and 10 NG-MAST STs (Figure 1a) . The 25 porB1b CRO Red isolates displayed 20 different porB sequences, dispersing along the entire porB1b phylogenetic tree and 21 NG-MAST STs, with the largest ST (#270) comprising 3 isolates (Figure 1b) . The 19 porB1b CRO S isolates included 16 porB1b sequences, which were dispersed among the porB1b sequences of the CRO Red isolates along the phylogenetic tree, and 18 NG-MAST STs (ST421 comprising 2 isolates, while all other STs had a single isolate) (Figure 1b) . Three STs (ST1691, ST1972 and ST2288) were present in both CRO Red and CRO S isolates, while other STs were observed only in one susceptibility class or the other.
Discussion
We examined mutations in PorB (porB), MtrR (mtrR), PBP2 (penA) and PBP1 (ponA) in N. gonorrhoeae isolates that had reduced susceptibility to ceftriaxone (CRO Red , MIC¼ 0.125-0.25 mg/L) or were susceptible to ceftriaxone (CRO S , MIC¼0.004-0.016 mg/L). Our results show that the porB1b allele (expressing PIB) is required but is insufficient for conferring reduced susceptibility to ceftriaxone in N. gonorrhoeae isolates. Approximately 40% of the CRO S isolates (13/32) also exhibited a porB1b genotype (expressing PIB), suggesting that other loci in porB1b isolates Liao et al.
are involved in mediating increasing ceftriaxone MICs. The G120/ A121 mutations of PorB were not associated with increasing ceftriaxone MICs, supporting other reports. 11 Tanaka et al. reported that G120/A121 mutations were only found in a ceftriaxone-resistant strain (MIC¼ 0.5 mg/L), but not in four ceftriaxone-susceptible strains (MIC≤ 0.004 mg/L). The transpeptidase domain of gonococcal PBP2 was polymorphic and exhibited 15 mutation patterns, but the 'mosaic' PBP2 (pattern X), which was first associated with reduced susceptibility to oral cephalosporins (i.e. cefixime), 9 was not present in the N. gonorrhoeae isolates of our study. Six of the 15 mutation patterns in PBP2 identified in the present study are new. The most common mutation patterns for all isolates combined (n¼ 60) were patterns V, XXI and XXVII. By comparison, the most common mutation patterns in isolates from Sydney, Australia, were patterns XII, X and XIII, 38 whereas in Korea, pattern XIII was most common. 15 Interestingly, patterns XIII and XVII or XVIII were only present in CRO Red isolates in both the study by Whiley et al. 38 (MIC ¼ 0.06-0.12 mg/L; 17.9% of 28 isolates) and in the present study (MIC ¼ 0.125-0.25 mg/L; 21.4% of 28 CRO Red isolates). These two patterns contained combinations of A501V and P551S (pattern XIII) or A501V and G542S (pattern XVII or XVIII) mutations, which have been associated with an increased ceftriaxone MIC. 39 We conclude that a combination of A501V/Tand G542S or A501V/T and P551S/L mutations, and probably mutations at other residues in PBP2, are required for increasing ceftriaxone MICs. Genetic confirmation and structure/function analysis of these mutations are warranted.
Over 90% of both CRO Red and CRO S N. gonorrhoeae isolates contained an '2A' deletion in the 13 bp inverted repeat sequence of the mtrR promoter, indicating that such a deletion is not implicated in reduced susceptibility to ceftriaxone, unlike for penicillin resistance. 17 However, A39T/H105Y or G45D/H105Y double mutations in MtrR were only present in CRO Red isolates. Mutation A39T or G45D, either singly or in combination, diminishes binding of the MtrR repressor to the mtrC/D/E promoter and thereby increases resistance to hydrophobic agents. 16, 18, 19, 40 The H105Y mutation could inhibit MtrR dimerization and subsequently 270  270  421  2288  2288  2160  421  270  1405  1393  2761  2051  1972  1972  1972  2107  2831  2781  2758  2908  1866  1866  2771  2792  2813  1739  1731  2804  3290  3361  2832  2501  2008  3363  3359  2786  2066  2811  1614  2765  2828  566  1870  1691  0.01   SH200851  Sh200805  92  42  81  71  151  SH200804  106  SH200819  79  44  155  108  SH200839  139  137  15  19  141  SH200818  SH20089  144  68  83  67  SH200807  20  SH200830  Sh200890  138  43  80  SH200845  SH200853  27  38  66  Sh200848  73  127 Molecular determinants associated with reduced susceptibility to ceftriaxone in N. gonorrhoeae isolates
